89bio Stock

89bio ROA

Delisted·Oct 29, 2025

The Return on Assets (ROA) of 89bio (ETNB) as of Aug 16, 2026 is -76.68 %. In the previous year, Return on Assets (ROA) was -23.85 % — a change of 221.58% (lower).

ROA

-76.68 %

YoY

221.58%

Last updated:

In 2026, 89bio's return on assets (ROA) was -76.68 %, a 221.58% increase from the -23.85 % ROA in the previous year.

Access this data via the Eulerpool API

89bio Stock analysis

What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California. 89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry. 89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism. The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body. In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion. Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.

ROA Details

Understanding 89bio's Return on Assets (ROA)

89bio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing 89bio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider 89bio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in 89bio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about 89bio stock

Return on Assets (ROA) of 89bio is -76.68 % in 2026.

Return on Assets (ROA) of 89bio changed from -23.85 % to -76.68 %, representing a 221.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) 89bio since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s 89bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — 89bio

All Key Metrics — 89bio